Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. [electronic resource]
Producer: 20081223Description: 448-53 p. digitalISSN:- 1600-0609
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Humans
- Lymphocyte Count
- Lymphoma, Large B-Cell, Diffuse -- blood
- Male
- Middle Aged
- Predictive Value of Tests
- Prednisone -- administration & dosage
- Regression Analysis
- Retrospective Studies
- Risk Factors
- Rituximab
- Survival Rate
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.